Deal signed for Oman’s first penicillin project

Pharma landmark: Pen-G, jointly owned by MHD LLC and Ali bin Moosa al Balushi, is a state-of-the-art fermentation plant for the manufacture of key pharmaceutical start-up material at the Sohar Freezone

BUSINESS REPORTER

MUSCAT, APRIL 9

Mohsin Haider Darwish LLC (MHD LLC), one of the largest and pioneering business houses in the Sultanate of Oman, has signed an agreement with Ali bin Moosa al Balushi, National Bank of Oman (NBO), and Sohar Port and Freezone for the establishment of a first-of-its-kind pharmaceutical manufacturing facility in the Middle East and North Africa (MENA) region – Penicillin General Integrated Industrial Company (Pen-G).

Under the agreement, Pen-G will be jointly owned by MHD LLC and Ali bin Moosa al Balushi and will establish a state-of-the-art fermentation plant for the manufacture of key pharmaceutical start-up material at the Sohar Freezone. NBO will be participating as the primary bank through which the project is being financed.

The signing ceremony took place on April 6, 2022, at the Pen-G Head Office in Ghala. Present at the signing ceremony were Ali bin Moosa al Balushi; Mohammed bin Abdullah al Kharusi – Chief Executive Officer, MHD LLC; Abdullah bin Zahran al Hinai, Chief Executive Officer, National Bank of Oman; and Omar bin Mahmood al Mahrizi, Chief Executive Officer of Sohar Freezone and Deputy Chief Executive Officer of Sohar Port. Also in attendance at the event were other members of the executive and senior management of each of the four companies.

Commenting on the project, Mohammed al Kharusi said, “As of 2020, the global pharmaceutical industry generated revenues of $1.27 trillion, representing significant growth over the past two decades. Our objective with Pen-G is twofold. First, we would like to officially put Oman on the world map for raw materials for start-up medicine and enter this lucrative industry, and second, we would like to further our goal of establishing ourselves as a key contributor to Oman Vision 2040 and, by extension, to the government’s national diversification efforts. Furthermore, our location at the Sohar Freezone, right next to the largest industrial port in the country, provides us with ready access to global trade routes between Asia and Europe for both acquisition of raw materials as well as export of our product.”

The Pen-G fermentation plant will be the first of its kind in the region and has been initially designed to have two blocks for the manufacture of Penicillin-G and 6-APA (Amino Penicillanic Acid) respectively. These are key start-up materials for the most widely used group of antibiotics, penicillin, and cephalosporins. There are also plans to eventually add a further block for the manufacture of key start-up materials for Erythromycin. Furthermore, the plant has been designed from the ground up to comply wholly with Good Manufacturing Practices (GMP) regulations, ensuring all products manufactured are to global standards.

The project was the brainchild of Ali bin Moosa al Balushi, a proven, dynamic, multi-disciplined project director and programme manager. He has been a banker for close to two decades before he plunged into the pharmaceutical business, implementing, and providing complete project life-cycle management services for various pharma projects in India and Oman. Commenting on the Pen-G project, he said, “This project is a core part of my constantly evolving dream to build value in Oman in the Pharma sector. Penicillin G represents value addition at the raw material stage of antibiotic medicine manufacturing – an area currently dominated by China. Once completely operational, this plant will cater to the demand for Penicillin GK raw material amounting to nearly 10 per cent of the world’s consumption.”

Omar bin Mahmood al Mahrizi said, “The growth of the Sohar pharma cluster is an important step forward in the development of the Port and Freezone with far-reaching benefits to the local community, both in terms of investment and access to the finished product. This pharma project, the second project after our animal vaccination facility, will add significant value to all three of our objectives. We are confident that the plant operated by Penicillin General Integrated Industrial Company will provide the impetus for further investment in the pharmaceutical industry and the potential for Sohar to become the main hub for the industry in the region.”